ArticleCureus2025
Follicular Lymphoma of the Breast With Secondary Central Nervous System Transformation and Concurrent Metastatic Melanoma: Report of a Rare Case.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Follicular lymphoma (FL) rarely presents in the breast and even less frequently transforms with secondary central nervous system (CNS) involvement. The coexistence of transformed FL with metastatic melanoma is exceptionally rare and presents significant diagnostic and therapeutic challenges. We report the case of an elderly female initially diagnosed with primary breast follicular lymphoma (FL), managed with surveillance. Over subsequent years, she experienced multiple relapses, treated with bendamustine-rituximab and later lenalidomide, achieving remission. Fourteen years after initial diagnosis, she developed CNS symptoms with cerebellar lesions; resection revealed transformed diffuse large B-cell lymphoma (DLBCL) of germinal center origin (CD5+, CD10+, BCL2, BCL6, MYC+, Ki-67 ~70%). Concurrent metastatic melanoma was also diagnosed. Given the rarity of CNS-transformed FL and the absence of standard guidelines, her case was managed as primary CNS lymphoma. She received high-dose methotrexate, rituximab, and temozolomide with Stereotactic Body Radiotherapy (SBRT) for melanoma. Despite significant intracranial progression, she remained largely asymptomatic and prioritized quality of life, highlighting the challenges of individualized care in complex dual malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.